Compare AbbVie Inc (ABBV) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Sony Group Corp — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Sony Group Corp trades at $23.46 (market cap $139.99B). The key difference: AbbVie Inc is far larger — about 3.1× Sony Group Corp's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | SONY | |
|---|---|---|
Market Cap | $438.19B | $139.99B |
Sector | Health | Technology |
52-Week High | $263.58 | $30.26 |
52-Week Low | $197.38 | $19.32 |
Enterprise Value | $502.45B | $137.89B |
Dividend Yield | 2.79% | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Sony stock trades at $23.46, up 1.56% with bullish technical indicators and strong analyst support. The company shows solid revenue growth with $12.96T in 2025 sales and improved profitability, though 2026 projections indicate potential margin pressure. Recent catalysts include the record-breaking Spider-Man film performance and a $6.3B joint venture with TSMC for next-generation image sensors, positioning Sony for continued entertainment and technology leadership.
Sony presents a compelling investment case with strong entertainment franchises and technological innovation, though investors should monitor execution risks in the gaming transition and potential margin compression. Wall Street remains overwhelmingly bullish with 11 buy ratings and a 29.75% upside potential, but the stock faces challenges from currency volatility and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
